The effect of ruboxistaurin on nephropathy in type 2 diabetes

Diabetes Care

Volumn 28, Issue 11, 2005, Pages 2686-2690

  Tuttle, Katherine R ^a,f   Bakris, George L ^b   Toto, Robert D ^c   McGill, Janet B ^d   Hu, Kuolung ^e   Anderson, Pamela W ^e  

^a SACRED HEART MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f Research Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; HEMOGLOBIN A1C; PLACEBO; RENIN INHIBITOR; RUBOXISTAURIN; CREATININE; ENZYME INHIBITOR; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CALCULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBDURAL HEMATOMA; SYSTOLIC BLOOD PRESSURE; AFRICAN AMERICAN; CAUCASIAN; COMPARATIVE STUDY; ETHNOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICS; TIME; UNITED STATES;

AFRICAN AMERICANS; AGED; ALBUMINURIA; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INDOLES; MALE; MALEIMIDES; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; UNITED STATES;

EID: 28644442122     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/diacare.28.11.2686     Document Type: Article

References (21)

1. Nelson RG, Bennett PH, Nowler WC, Pettitt DJ: Kidney diseases in diabetes. In Diabetes in America. Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett C, Eds. Bethesda, MD, The National Institutes of Health, 1995, p. 349-400
2. US Renal Data System: Annual data report: incidence and prevalence, 2004. Am J Kidney Dis 45:S77-S80, 2004
3. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.NEngl J Med 329:977-986, 1993
4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
8. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 124:627-632, 1996
9. Hanson HP, Tauber-Lassen E, Jensen BR, Parving HH: Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 62:220-228, 2002
10. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272:728-731, 1996
11. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439-447, 2000
12. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961, 2004
13. Tuttle KR, Anderson PW: A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C β inhibition. Am J Kidney Dis 42:456-465, 2003
14. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL: Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 89:11059-11063, 1992
15. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, Wilkinson-Berka JL, Gilbert RE: Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52:512-518, 2003
16. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.AmJ Kidney Dis 39:S1-S266, 2002
17. American Diabetes Association: Clinical practice recommendations 2002: standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 25 (Suppl. 1):S33-S49, 2002
18. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
19. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
20. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type diabetic patients with nephropathy. Circulation 110:921-927, 2004
21. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320, 2004